A recent conversation with an industry veteran highlighted that pharmaceutical R&D costs can increase more than 15-fold and timelines can extend an additional 2 years due to an unanticipated change in formulation strategy. Since this has the potential to derail an entire program or even an entire company, the best protection is to gather more data and more accurate data, earlier.
At the preclinical stage when multiple teams are trying to prioritize the use of available milligrams of material, the only viable option to making informed decisions is doing more with less, without sacrificing quality.
For solubility, this was never an option before, but The Solubility Company’s SPA® Platform has now changed the game. SPA® generates timely solubility data from less than 100 µg of material on blinded samples with industry standard accuracy.
Know your molecule early to avoid the surprises, reduce the risk, and formulate with confidence – talk to our experts.
Our Quakertown, PA and Helsinki, Finland laboratories have streamlined sample submission processes, shaving further time off the already impressive data turn around of The Solubility Company’s SPA® Platform.
If you’re looking to Research Smart and Deliver Early, click here to drop us a message!
Viikinkaari 4
00790 Helsinki
FINLAND
1 Broadway
Cambridge MA 01242
United States
Workshop: Mitigating Risk in Small Molecule Drug Development
6 February 2025, MassBioHub, Cambridge, MA